Wal-Mart's on top. Which other companies made the top 50 this year? (more)

Best big companies to work for

See more than 30 companies that made both the Fortune 1000 and Best Companies to Work For lists this year. (more)

20 best investments

These 20 stocks offered some of the best returns to shareholders last year. Will they keep rising? (more)

Special Offer:

The Fortune 500's biggest losers

14 of 20

14. Schering-Plough

• See more Fortune 500 data for Schering-Plough

Fortune 500 rank: 212

2007 loss: $1.47 billion

Drugs are a blockbuster business. So when Schering-Plough's patent on allergy medication Claritin expired in 2003, the company needed to do something dramatic. It got a new CEO and launched a restructuring plan, which culminated with last year's $16 billion acquisition of European drugmaker Organon BioSciences.

Schering took a $4 billion charge related to the deal, which tanked earnings. But 2008 may not be much better: Vytorin, a cholesterol drug combination from Schering-Plough and Merck, is under fire from lawmakers who say the companies misrepresented its effectiveness.

NEXT: Sovereign Bancorp

Last updated April 24 2008: 11:01 AM ET

Email | Print |

Digg this story |

RSS

* : Time reflects local markets trading time.† - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges.• Disclaimer

Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.